Ultragenyx Pharmaceutical Inc (RARE) was one of the Russell 2000's biggest losers for Friday January 15 as the stock slid 6.39% to $77.04, a loss of $-5.26 per share. Starting at an opening price of $78.13 a share, the stock traded between $76.29 and $80.83 over the course of the trading day. Volume was 501,948 shares over 6,927 trades, against an average daily volume of 456,412 shares and a total float of 38.83 million.
The losses send Ultragenyx Pharmaceutical Inc down to a market cap of $2.99 billion. In the last year, Ultragenyx Pharmaceutical Inc has traded between $137.05 and $48.96, and its 50-day SMA is currently $100.79 and 200-day SMA is $97.10.
Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development & commercialization of novel products for treatment of rare &ultra-rare diseases, with focus on debilitating metabolic genetic diseases.
Ultragenyx Pharmaceutical Inc is based out of Novato, CA and has some 218 employees. Its CEO is Emil D. Kakkis.
For a complete fundamental analysis analysis of Ultragenyx Pharmaceutical Inc, check out Equities.com’s Stock Valuation Analysis report for RARE. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer